- Home
- LDP vs STOK Comparison
LDP vs STOK Comparison
Compare LDP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- STOK
- Stock Information
- Founded
- LDP 2012
- STOK 2014
- Country
- LDP United States
- STOK United States
- Employees
- LDP N/A
- STOK N/A
- Industry
- LDP Finance Companies
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- LDP Finance
- STOK Health Care
- Exchange
- LDP Nasdaq
- STOK Nasdaq
- Market Cap
- LDP 607.2M
- STOK 721.4M
- IPO Year
- LDP N/A
- STOK 2019
- Fundamental
- Price
- LDP $20.43
- STOK $11.68
- Analyst Decision
- LDP
- STOK Strong Buy
- Analyst Count
- LDP 0
- STOK 8
- Target Price
- LDP N/A
- STOK $21.83
- AVG Volume (30 Days)
- LDP 102.5K
- STOK 667.4K
- Earning Date
- LDP 01-01-0001
- STOK 11-05-2024
- Dividend Yield
- LDP 7.91%
- STOK N/A
- EPS Growth
- LDP N/A
- STOK N/A
- EPS
- LDP N/A
- STOK N/A
- Revenue
- LDP N/A
- STOK $16,742,999.00
- Revenue This Year
- LDP N/A
- STOK $103.66
- Revenue Next Year
- LDP N/A
- STOK N/A
- P/E Ratio
- LDP N/A
- STOK N/A
- Revenue Growth
- LDP N/A
- STOK 81.08
- 52 Week Low
- LDP $16.16
- STOK $4.09
- 52 Week High
- LDP $20.30
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- LDP 35.63
- STOK 44.25
- Support Level
- LDP $20.12
- STOK $10.61
- Resistance Level
- LDP $21.15
- STOK $12.58
- Average True Range (ATR)
- LDP 0.28
- STOK 0.95
- MACD
- LDP -0.09
- STOK -0.12
- Stochastic Oscillator
- LDP 22.46
- STOK 28.34
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.